Vifor Pharma Group is a global pharmaceuticals company. It holds a leading position in
all its core business activities and consists of the following companies: Vifor Pharma and
Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma is dedicated to identifying and supporting under-served therapeutic areas. As pioneers in iron-based
therapies, we have, and continue to demonstrate strong scientific, regulatory and commercial expertise to identify
opportunities that help create, develop and mature markets.
We understand what it means to take calculated risks, and to determine the next best breakthrough for our patients
and our innovative medical treatments.
At Pharmacosmos, we are specialists in iron therapy. We develop, manufacture and market medicines for the treatment of iron deficiency anaemia in humans and animals. We are furthermore specialists in developing and producing advanced carbohydrates for pharmaceutical and technical uses.
Across the world, more than 1 billion people live with iron deficiency anaemia, making it one of the largest global health challenges of our time. At Pharmacosmos, we want to change the way iron deficiency is prevented and treated in humans and animals. We are inspired by one central question: How can we continue to improve patient safety, recovery and convenience and thereby achieve better outcomes?
We seek the answer by staying at the scientific forefront of iron and carbohydrate technology – partnering with dedicated people and leading organisations to deliver the best possible treatments for human and veterinary use. In this way, we improve more than iron complexes and carbohydrates, we improve the quality of lives.
We have our headquarters in Holbaek, Denmark and affiliates in the US, China, UK, Ireland, Germany, Denmark, Sweden and Norway.
Werfen develops, manufactures and distributes instruments, reagents and data management solutions, for in vitro diagnostic testing – at the point-of-care and in the lab.
Our comprehensive and integrated Acute Care Diagnostics line is comprised of whole-blood testing systems to help clinicians and laboratorians achieve better patient outcomes, lower total cost of care, assure regulatory compliance and enhance operational efficiency in hospital Acute Care settings. From the CVOR and Cath Lab, to ICUs and EDs, our Acute Care Diagnostic solutions address today’s healthcare challenges. Key products include our GEM Premier blood gas systems, GEM Premier ChemSTAT and Avoximeter 1000E, as well as the whole-blood hemostasis family, featuring ROTEM, Hemochron and VerifyNow systems.
Our Hemostasis line is comprised of in vitro diagnostic systems, reagents, information management used to diagnose and guide treatment of thrombotic and bleeding disorders. Our solutions improve the quality of patient care, lower total cost, and assure regulatory compliance in the clinical laboratory. Key products include our industry-leading ACL TOP Family 50 Series Hemostasis Testing Systems, HemoCell Specialized Lab Automation, HemosIL Assays, and HemoHub Intelligent Data Manager.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited, headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: haematology, immunotherapy and critical care.
Sponsors and Exhibitors
Safe and high-quality autologous blood in 30 minutes. Without the need for electricity, equipment, extensive training, nor expensive consumables.
The innovative HemoClear blood filter recently obtained a European market authorization and is now available to the European markets.
At HemoClear, we are on a mission to create innovative medical devices that focus on severe or life-threatening diseases and have limited available or affordable treatment options. We’re privileged with our founder Dr Arno Nierich, a Cardiac Anaesthesiologist-Intensivist, who translates with passion, practical experiences into simple and accessible device solutions.
Medical inquiries email@example.com | Busines inquiries firstname.lastname@example.org | www.hemoclear.com
HemoSonics is revolutionizing point-of-care bleeding management by bringing you the Quantra® Hemostasis Analyzer - a novel, closed-cartridge viscoelastic (VET) assay based on an innovative ultrasound technology. When time to treatment is critical, the Quantra System offers rapid, precise, and easy to interpret coagulation results that enable clinicians to make quick and informed bleeding management decisions in point-of-care (POC) settings such as the operating theatre or ICU.
The Quantra System is both CE marked and FDA cleared for point-of-care use in perioperative patients 18 years or older. QPlus® cartridge is indicated for cardiovascular or major orthopedic surgery. QStat® cartridge is indicated for trauma or liver surgery (currently available outside of the US only). Because of its simple, intuitive, and safe POC workflow from sample collection to cartridge disposal, the Quantra is the first VET assay specifically indicated by FDA for point-of-care use. For more information, visit: www.HemoSonics.com/nata2021
I-SEP is a French Medtech, based in Nantes, specialized in intraoperative cells salvage (IOCS) and Patient Blood Management. I-SEP has developed and patented an innovative technology for the separation of blood components.
Our ambition is to become the first laboratory to market an autotransfusion system capable of recovering both red blood cells and platelets during hemorrhagic surgery, with ergonomic and intuitive equipment.
i-SEP works closely with referent surgical and anesthesiologist teams with the aim of improving patients benefits, simplifying the work of clinicians and contributing to reduce hospital costs.
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and connectivity solutions. In 1995, Masimo debuted SET® Measure-through Motion and Low Perfusion™ pulse oximetry, estimated to be used on more than 100 million patients annually. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry, allowing noninvasive and continuous monitoring of additional physiologic parameters that previously could only be measured invasively, such as total hemoglobin (SpHb®). We continue to advance noninvasive monitoring, connectivity, and automation with innovations like the Root® patient monitoring and connectivity hub and the Patient SafetyNet™ supplemental remote monitoring solution. For more information www.masimo.com
Making healthcare better is our priority, and we believemedical technology can play an even greater role in improving people’s lives.With challenges facing families and healthcare systems— such as rising costs, aging populations, and the burden of chronic disease— we are using the power of technology to take healthcare Further, Together.
Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employingmore than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value— for healthcare systems, providers, and the people they serve. Learn more at Medtronic.com.
Nordic Pharma is a privately-owned international pharmaceutical company which focuses on the development and commercialization of niche hospital, and orphan products to address unmet medical needs. Nordic Pharma expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Its portfolio of therapeutic areas includes rheumatology, women’s health and critical care.
Nordic Pharma commercializes Trasylol® (aprotinin), a medicine indicated for prophylactic use to reduce blood loss and blood transfusion in adult patients who are at high risk of major blood loss undergoing isolated cardiopulmonary bypass graft surgery (i.e. coronary artery bypass graft surgery that is not combined with other cardiovascular surgery).
Founded and managed by the Lacorte brothers, PharmaNutra S.p.A. was born in 2003 with the aim of developing nutritional supplements and innovative medical devices, overseeing the whole production process, from the development of proprietary raw materials to the distribution of the finished product. With its products distributed worldwide, in less than 20 years the company has succeeded in making its mark as a leading player in the iron-based oral nutritional supplements market, where it boasts major patents linked to Sucrosomial® Technology, and it is also considered to be one of the emerging top players in the sector of medical devices for the recovery of joint capacity. https://www.pharmanutra.it/
Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions.
In the fields of haematology, urinalysis, haemostasis, oncology, flow cytometry and essential healthcare, we offer fully automated workflow solutions at a premium level, ensuring that we provide physicians and patients with options tailored to their specific needs. As a clinical value related to patient blood management, we offer tools to assess iron deficiency and bleeding risk.
Sysmex Europe GmbH located near Hamburg, Germany is a subsidiary of the Sysmex Corporation in Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA). For more information on how we are shaping the advancement of healthcare, visit www.sysmex-europe.com